Listed

Context Therapeutics Inc.

CNTXNasdaqCIK 1842952HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$15.0m, Q2 FY2026
Net income−$14.6m, Q2 FY2026
Context Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating income$m(6.2)Operating income, Q3 FY2023, three months to 2023-09-30−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure(6.9)Operating income, Q4 FY2023, three months to 2023-12-31−$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001842952-25-000028. Derived: 12-month figure less the 9-month figure.Report this figure(3.8)Operating income, Q1 FY2024, three months to 2024-03-31−$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure(3.1)Operating income, Q2 FY2024, three months to 2024-06-30−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure(18.7)Operating income, Q3 FY2024, three months to 2024-09-30−$18.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure(4.3)Operating income, Q4 FY2024, three months to 2024-12-31−$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure(5.5)Operating income, Q1 FY2025, three months to 2025-03-31−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(9.8)Operating income, Q2 FY2025, three months to 2025-06-30−$9.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure(10.6)Operating income, Q3 FY2025, three months to 2025-09-30−$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure(13.8)Operating income, Q4 FY2025, three months to 2025-12-31−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure(9.3)Operating income, Q1 FY2026, three months to 2026-03-31−$9.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(15.0)Operating income, Q2 FY2026, three months to 2026-06-30−$15.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(5.9)Net income, Q3 FY2023, three months to 2023-09-30−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure(6.8)Net income, Q4 FY2023, three months to 2023-12-31−$6.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-20, accession 0001842952-25-000028. Derived: 12-month figure less the 9-month figure.Report this figure(3.7)Net income, Q1 FY2024, three months to 2024-03-31−$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure(2.3)Net income, Q2 FY2024, three months to 2024-06-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure(17.5)Net income, Q3 FY2024, three months to 2024-09-30−$17.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure(3.3)Net income, Q4 FY2024, three months to 2024-12-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Net income, Q1 FY2025, three months to 2025-03-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure(8.8)Net income, Q2 FY2025, three months to 2025-06-30−$8.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure(9.7)Net income, Q3 FY2025, three months to 2025-09-30−$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure(13.0)Net income, Q4 FY2025, three months to 2025-12-31−$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure(8.7)Net income, Q1 FY2026, three months to 2026-03-31−$8.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure(14.6)Net income, Q2 FY2026, three months to 2026-06-30−$14.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Diluted EPS$ per share(0.37)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figurenot reported(0.23)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure(0.04)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure(0.22)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figurenot reported(0.05)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(0.09)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure(0.10)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figurenot reported(0.09)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(0.15)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Basic EPS$ per share(0.37)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figurenot reported(0.23)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure(0.04)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure(0.22)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figurenot reported(0.05)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(0.09)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure(0.10)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figurenot reported(0.09)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(0.15)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure

Balance sheet

Cash and equivalents$43.0m, Q2 FY2026
Shareholders' equity$38.2m, Q2 FY2026
Context Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m21.7Cash and equivalents, Q3 FY2023, at 2023-09-30$21.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001842952-23-000085.Report this figure14.4Cash and equivalents, FY2023, at 2023-12-31$14.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-20, accession 0001842952-25-000028.Report this figure10.1Cash and equivalents, Q1 FY2024, at 2024-03-31$10.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0001842952-24-000035.Report this figure102Cash and equivalents, Q2 FY2024, at 2024-06-30$101.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-07, accession 0001842952-24-000065.Report this figure84.8Cash and equivalents, Q3 FY2024, at 2024-09-30$84.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure94.4Cash and equivalents, FY2024, at 2024-12-31$94.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-23, accession 0001628280-26-020498.Report this figure89.4Cash and equivalents, Q1 FY2025, at 2025-03-31$89.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure83.5Cash and equivalents, Q2 FY2025, at 2025-06-30$83.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure76.9Cash and equivalents, Q3 FY2025, at 2025-09-30$76.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure66.0Cash and equivalents, FY2025, at 2025-12-31$66.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure54.5Cash and equivalents, Q1 FY2026, at 2026-03-31$54.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure43.0Cash and equivalents, Q2 FY2026, at 2026-06-30$43.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Current assets$m23.0Current assets, Q3 FY2023, at 2023-09-30$23.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001842952-23-000085.Report this figure16.0Current assets, FY2023, at 2023-12-31$16.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-20, accession 0001842952-25-000028.Report this figure11.0Current assets, Q1 FY2024, at 2024-03-31$11.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0001842952-24-000035.Report this figure103Current assets, Q2 FY2024, at 2024-06-30$102.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0001842952-24-000065.Report this figure86.1Current assets, Q3 FY2024, at 2024-09-30$86.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure97.9Current assets, FY2024, at 2024-12-31$97.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-23, accession 0001628280-26-020498.Report this figure92.7Current assets, Q1 FY2025, at 2025-03-31$92.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure86.9Current assets, Q2 FY2025, at 2025-06-30$86.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure79.1Current assets, Q3 FY2025, at 2025-09-30$79.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure68.4Current assets, FY2025, at 2025-12-31$68.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure58.5Current assets, Q1 FY2026, at 2026-03-31$58.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure45.8Current assets, Q2 FY2026, at 2026-06-30$45.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Total assets$m23.0Total assets, Q3 FY2023, at 2023-09-30$23.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001842952-23-000085.Report this figure16.1Total assets, FY2023, at 2023-12-31$16.1m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-20, accession 0001842952-25-000028.Report this figure11.1Total assets, Q1 FY2024, at 2024-03-31$11.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0001842952-24-000035.Report this figure103Total assets, Q2 FY2024, at 2024-06-30$102.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0001842952-24-000065.Report this figure86.3Total assets, Q3 FY2024, at 2024-09-30$86.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure98.1Total assets, FY2024, at 2024-12-31$98.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-23, accession 0001628280-26-020498.Report this figure93.0Total assets, Q1 FY2025, at 2025-03-31$93.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure87.2Total assets, Q2 FY2025, at 2025-06-30$87.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure79.2Total assets, Q3 FY2025, at 2025-09-30$79.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure68.5Total assets, FY2025, at 2025-12-31$68.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure58.9Total assets, Q1 FY2026, at 2026-03-31$58.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure46.1Total assets, Q2 FY2026, at 2026-06-30$46.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Current liabilities$m4.6Current liabilities, Q3 FY2023, at 2023-09-30$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001842952-23-000085.Report this figure4.2Current liabilities, FY2023, at 2023-12-31$4.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-20, accession 0001842952-25-000028.Report this figure2.6Current liabilities, Q1 FY2024, at 2024-03-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0001842952-24-000035.Report this figure1.6Current liabilities, Q2 FY2024, at 2024-06-30$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0001842952-24-000065.Report this figure2.3Current liabilities, Q3 FY2024, at 2024-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure2.7Current liabilities, FY2024, at 2024-12-31$2.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-23, accession 0001628280-26-020498.Report this figure1.9Current liabilities, Q1 FY2025, at 2025-03-31$1.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure4.6Current liabilities, Q2 FY2025, at 2025-06-30$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure6.0Current liabilities, Q3 FY2025, at 2025-09-30$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure8.0Current liabilities, FY2025, at 2025-12-31$8.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure6.5Current liabilities, Q1 FY2026, at 2026-03-31$6.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure7.9Current liabilities, Q2 FY2026, at 2026-06-30$7.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Total liabilities$m4.6Total liabilities, Q3 FY2023, at 2023-09-30$4.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001842952-23-000085.Report this figure4.2Total liabilities, FY2023, at 2023-12-31$4.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-20, accession 0001842952-25-000028.Report this figure2.6Total liabilities, Q1 FY2024, at 2024-03-31$2.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0001842952-24-000035.Report this figure1.6Total liabilities, Q2 FY2024, at 2024-06-30$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0001842952-24-000065.Report this figure2.5Total liabilities, Q3 FY2024, at 2024-09-30$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure2.9Total liabilities, FY2024, at 2024-12-31$2.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-23, accession 0001628280-26-020498.Report this figure2.0Total liabilities, Q1 FY2025, at 2025-03-31$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure4.6Total liabilities, Q2 FY2025, at 2025-06-30$4.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure6.1Total liabilities, Q3 FY2025, at 2025-09-30$6.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure8.0Total liabilities, FY2025, at 2025-12-31$8.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure6.7Total liabilities, Q1 FY2026, at 2026-03-31$6.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure8.0Total liabilities, Q2 FY2026, at 2026-06-30$8.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure
Shareholders' equity$m18.4Shareholders' equity, Q3 FY2023, at 2023-09-30$18.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure11.9Shareholders' equity, FY2023, at 2023-12-31$11.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-23, accession 0001628280-26-020498.Report this figure8.4Shareholders' equity, Q1 FY2024, at 2024-03-31$8.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure101Shareholders' equity, Q2 FY2024, at 2024-06-30$101.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure83.9Shareholders' equity, Q3 FY2024, at 2024-09-30$83.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure95.3Shareholders' equity, FY2024, at 2024-12-31$95.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure91.0Shareholders' equity, Q1 FY2025, at 2025-03-31$91.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure82.5Shareholders' equity, Q2 FY2025, at 2025-06-30$82.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure73.2Shareholders' equity, Q3 FY2025, at 2025-09-30$73.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure60.5Shareholders' equity, FY2025, at 2025-12-31$60.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure52.2Shareholders' equity, Q1 FY2026, at 2026-03-31$52.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure38.2Shareholders' equity, Q2 FY2026, at 2026-06-30$38.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure

Cash flow

Operating cash flow−$7.0m, Q2 FY2026
Capital expenditure$18.5k, Q2 FY2026
Context Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(3.5)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001842952-24-000085. Derived: 9-month figure less the 6-month figure.Report this figure(7.2)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0001842952-25-000028. Derived: 12-month figure less the 9-month figure.Report this figure(4.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure(3.4)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0001842952-25-000081. Derived: 6-month figure less the 3-month figure.Report this figure(1.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049533. Derived: 9-month figure less the 6-month figure.Report this figure(4.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure(5.0)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(5.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053347. Derived: 6-month figure less the 3-month figure.Report this figure(6.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$6.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049533. Derived: 9-month figure less the 6-month figure.Report this figure(8.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure(11.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$11.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure(7.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$7.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053347. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0001842952-24-000085. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001842952-25-000028. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-06, accession 0001842952-25-000081. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$7.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049533. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$33.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053347. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049533. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-23, accession 0001628280-26-020498. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$37.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$18.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053347. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)95.18m, Q2 FY2026
Context Therapeutics Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares16.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3015,966,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001842952-23-000085.Report this figure16.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3115,966,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0001842952-24-000035.Report this figure16.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3015,966,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0001842952-24-000065.Report this figure16.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3015,966,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001842952-24-000085.Report this figure16.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3115,966,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-07, accession 0001842952-25-000048.Report this figure55.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3054,958,635 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-06, accession 0001842952-25-000081.Report this figure80.5Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3080,481,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure95.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3195,186,935 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure95.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3095,186,935 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure95.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3095,185,187 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001628280-25-049533.Report this figure95.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3195,183,718 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001628280-26-031267.Report this figure95.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3095,183,718 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure

Shares outstanding: 91.88mShares outstanding, period not labelled, at 2026-08-0391,879,177 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053347.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.